EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Quarterly intravenous ibandronate injections provide continuing benefits in women with postmenopausal osteoporosis: DIVA study long-term extension



Quarterly intravenous ibandronate injections provide continuing benefits in women with postmenopausal osteoporosis: DIVA study long-term extension








(PDF emailed within 1 workday: $29.90)

Accession: 021628822

Download citation: RISBibTeXText



Related references

Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporosis International 23(6): 1769-1778, 2012

The diva study long-term extension: Maintained efficacy with quarterly intravenous ibandronate injection. 2007

Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone 46(3): 660-665, 2010

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Journal of Rheumatology 35(3): 488-497, 2008

Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis and Rheumatism 54(6): 1838-1846, 2006

Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women. Clinical Interventions in Aging 2(1): 65-72, 2007

Quarterly intravenous ibandronate for postmenopausal osteoporosis. Women's Health 4(3): 219-228, 2009

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporosis International 14(10): 801-807, 2003

Intermittent intravenous ibandronate injections are more effective than daily oral ibandronate for improving bone density at the hip: DIVA 2-year analysis. 2006

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. American Journal of Medicine 103(4): 298-307, 1997

Tri-monthly intravenous injections of ibandronate for treatment of postmenopausal osteoporosis. Journal of Bone & Mineral Research 16(Suppl 1): S406, September, 2001

Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporosis International 25(1): 349-357, 2014

Ibandronate injections in postmenopausal women with osteoporosis. Current Rheumatology Reports 9(1): 47; Discussion 48-9, 2007

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34(5): 890-899, 2004

Low incidence of flu-like illness with intravenous ibandronate injections: DIVA 2-year results. 2006